NASDAQ
612.33USD
-2.85 (-0.46%)
We have scored 79 news catalysts on Medpace Holdings, Inc. (MEDP) over the past 12 months. The biggest single-day move next to one of them came Feb 15, 2026, when MEDP closed +2.9%: “PSFE CLASS ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Paysafe Limited (PSFE) Investors of Securities Class Action Deadline on April 7, 2026”. Coverage across the window leans negative (average ticker sentiment −0.57). Most of the impact sits in price momentum and institutional appeal.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
17.1B
P/E
—
EPS
—
Beta
1.15
52W range
373-677.9
Day range
608.54–619.41
Open
615.12
Prev close
615.18
Volume
522.2K
Avg volume
293.7K
Dividend
0.00
IPO
2016-08-11
Analysts publish price targets on MEDP, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
10 analyst price targets from $515 to $692
as of 2026-08-27
The market is within 3% of the median target — broadly agreeing with the analysts.
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Medpace Holdings, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of Medpace Holdings, Inc., taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for MEDP: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
The reconstruction
The price sits at the 60th percentile of the published model spread, within 3% of the median, meaning the market broadly agrees with the consensus and has already paid for a smooth deceleration from 20% growth to roughly 8.5% annually while maintaining premium margins.
What the disagreement turns on
Does the Q4 2025 book-to-bill ratio of 1.04 represent a one-time miss or a structural downshift in demand, and can the quarterly new business awards and segment revenue mix actually measure this? The data can track the segment mix, but the specific book-to-bill ratio itself is not wired into the measurable tool coverage, leaving the core dispute partially unobservable until official reports.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
